Wellteq Management Webcast on May 25, 2021 Chief Medical Officer - Dr. George Gellert Biotech Investing
Lexaria's Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Biotech Investing
Lexaria's Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever Biotech Investing
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors Biotech Investing
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 Biotech Investing
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio's Abecma in Relapsed or Refractory Multiple Myeloma Biotech Investing
Six-and-a-Half-Year Outcomes for Opdivo in Combination with Yervoy Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma Biotech Investing
Opdivo Plus Yervoy with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial Biotech Investing
